KANGSTEM BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,635 KRW | -1.50% |
|
-0.94% | +10.02% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohnâs disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +10.02% | 107M | |
| +22.73% | 42.68B | |
| -3.45% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +8.20% | 24.94B | |
| -19.83% | 18.96B | |
| +29.71% | 12.3B | |
| -3.11% | 11.95B | |
| -2.01% | 11.55B |
- Stock Market
- Equities
- A217730 Stock
- News Kangstem Biotech Co., Ltd.
- Kang Stem Biotech to Raise 35.1 Billion Won via Shares Issuance; Shares Plunge 30%
